Chimeric antigen receptor (CAR) T cells have remarkable efficacy in patients with B cell acute lymphoblastic leukaemia (ALL), but have not been successful to date in patients with T cell ALL (T-ALL). Now, data from Pan and colleagues demonstrate the safety and impressive short-term efficacy of allogeneic donor-derived anti-CD7 CAR T cells in an early-phase clinical trial involving patients with relapsed and/or refractory T-ALL.

中文翻译：

---

用于 T-ALL 的抗 CD7 CAR T 细胞：令人印象深刻的早期疗效

嵌合抗原受体 (CAR) T 细胞在 B 细胞急性淋巴细胞白血病 (ALL) 患者中具有显着疗效，但迄今为止在 T 细胞 ALL (T-ALL) 患者中尚未取得成功。现在，Pan 及其同事的数据表明，在涉及复发和/或难治性 T-ALL 患者的早期临床试验中，同种异体供体来源的抗 CD7 CAR T 细胞的安全性和令人印象深刻的短期疗效。